AR083568A1 - FORMULACIONES LIQUIDAS DE CONJUGADO DE a INTERFERON DE ACCION PROLONGADA - Google Patents
FORMULACIONES LIQUIDAS DE CONJUGADO DE a INTERFERON DE ACCION PROLONGADAInfo
- Publication number
- AR083568A1 AR083568A1 ARP110103966A ARP110103966A AR083568A1 AR 083568 A1 AR083568 A1 AR 083568A1 AR P110103966 A ARP110103966 A AR P110103966A AR P110103966 A ARP110103966 A AR P110103966A AR 083568 A1 AR083568 A1 AR 083568A1
- Authority
- AR
- Argentina
- Prior art keywords
- liquid formulation
- interferon
- conjugate
- infa
- immunoglobulin
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 6
- 102000014150 Interferons Human genes 0.000 title abstract 4
- 108010050904 Interferons Proteins 0.000 title abstract 4
- 229940079322 interferon Drugs 0.000 title abstract 4
- 230000002035 prolonged effect Effects 0.000 title 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 239000007951 isotonicity adjuster Substances 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 150000005846 sugar alcohols Chemical class 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 229920002101 Chitin Polymers 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 229920001289 polyvinyl ether Polymers 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulación líquida en la cual es posible almacenar en forma estable por un largo periodo de tiempo un conjugado de INFa que tiene propiedades mejoradas de duración y estabilidad. Comprende un estabilizador que contiene una solución amortiguadora, un alcohol de azúcar, un tensioactivo no iónico y un agente isotónico. Al carecer de albúmina de suero humano y otros factores potencialmente perjudiciales para el organismo, la formulación líquida descarta riesgos de infecciones virales y garantiza una excelente estabilidad durante el almacenamiento para los conjugados de INFa de acción prolongada.Reivindicación 1: Una formulación líquida, que comprende una cantidad farmacéuticamente eficaz de un conjugado de interferón a de acción prolongada en el cual interferón a y una región Fc de inmunoglobulina están unidos covalentemente entre sí, y un estabilizante libre de albúmina que contiene una solución amortiguadora, un alcohol de azúcar, un tensioactivo no iónico y un agente isotónico. Reivindicación 8: La formulación líquida de la reivindicación 1, en donde el interferón a está unido covalentemente a la región Fc de inmunoglobulina por medio de un polímero no peptídico. Reivindicación 9: La formulación líquida de la reivindicación 8, en donde el polímero no peptídico se selecciona del grupo que consiste en polietilenglicol, polipropilenglicol, copolímeros de etilenglicol y propilenglicol polioles polioxietilados, polivinilalcohol, polisacáridos, dextrano, éter poliviniletílico, polímeros biodegradables, polímeros lipídicos, quitinas, ácido hialuránico, y una combinación de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100104383A KR101303388B1 (ko) | 2010-10-26 | 2010-10-26 | 지속형 인터페론 알파 결합체의 액상 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083568A1 true AR083568A1 (es) | 2013-03-06 |
Family
ID=45994559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103966A AR083568A1 (es) | 2010-10-26 | 2011-10-26 | FORMULACIONES LIQUIDAS DE CONJUGADO DE a INTERFERON DE ACCION PROLONGADA |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9669105B2 (es) |
| EP (1) | EP2632433A4 (es) |
| JP (1) | JP6047495B2 (es) |
| KR (1) | KR101303388B1 (es) |
| CN (2) | CN103228265A (es) |
| AR (1) | AR083568A1 (es) |
| AU (1) | AU2011321165B2 (es) |
| BR (1) | BR112013010311A8 (es) |
| CA (1) | CA2816052C (es) |
| MX (1) | MX349441B (es) |
| RU (1) | RU2613905C2 (es) |
| TW (1) | TWI494120B (es) |
| WO (1) | WO2012057525A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2440825C2 (ru) | 2007-07-10 | 2012-01-27 | Меди-Токс, Инк. | Жидкая фармацевтическая композиция ботулинического токсина |
| DK3878859T5 (da) | 2011-06-10 | 2024-06-10 | Hanmi Science Co Ltd | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
| SI2721062T1 (sl) | 2011-06-17 | 2019-03-29 | Hanmi Science Co., Ltd. | Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega |
| CN103611163A (zh) * | 2011-09-05 | 2014-03-05 | 韩美科学株式会社 | 一种包含干扰素α-缀合物的抗癌用药物组合物 |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
| MY168536A (en) * | 2012-11-06 | 2018-11-12 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| MX387560B (es) * | 2014-03-31 | 2025-03-18 | Hanmi Pharmaceutical Co Ltd | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| US20050002902A1 (en) | 1995-12-28 | 2005-01-06 | Liming Yu | Hybrid with interferon-alpha and an immunoglobulin Fc for treatment of tumors and viral infections |
| IL135186A0 (en) | 1997-09-23 | 2001-05-20 | Rentschler Biotechnologie Bmgh | LIQUID INTERFERON-β FORMULATIONS |
| CZ302005B6 (cs) * | 1998-03-26 | 2010-09-01 | Schering Corporation | Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující |
| KR19990085129A (ko) | 1998-05-14 | 1999-12-06 | 성재갑 | 안정한 α-인터페론 용액 제제 |
| CN1175901C (zh) | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
| US20030138403A1 (en) * | 2001-06-29 | 2003-07-24 | Maxygen Aps | Interferon formulations |
| US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| EP1641486B1 (en) | 2003-06-10 | 2012-04-18 | LG Life Sciences Ltd. | Stable, aqueous solution of human erythropoietin, not containing serum albumin |
| RU2352583C2 (ru) * | 2003-11-13 | 2009-04-20 | Ханми Фарм. Инд. Ко., Лтд. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ |
| US8110665B2 (en) * | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| MX2007014889A (es) | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| KR20080098504A (ko) | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| JP2008050320A (ja) | 2006-08-28 | 2008-03-06 | Toray Ind Inc | インターフェロン−β含有医薬組成物 |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| CN102112493B (zh) * | 2008-07-23 | 2015-04-01 | 韩美科学株式会社 | 包含具有三个官能性末端的非肽基聚合物的多肽复合物 |
| MX2012008453A (es) * | 2010-01-19 | 2012-11-21 | Hanmi Science Co Ltd | Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada. |
| US9867777B2 (en) * | 2010-01-19 | 2018-01-16 | Hanmi Science Co., Ltd. | Liquid formulations for long-acting G-CSF conjugate |
-
2010
- 2010-10-26 KR KR1020100104383A patent/KR101303388B1/ko not_active Expired - Fee Related
-
2011
- 2011-10-26 EP EP11836617.8A patent/EP2632433A4/en not_active Withdrawn
- 2011-10-26 US US13/881,976 patent/US9669105B2/en not_active Expired - Fee Related
- 2011-10-26 RU RU2013124059A patent/RU2613905C2/ru not_active IP Right Cessation
- 2011-10-26 CA CA2816052A patent/CA2816052C/en not_active Expired - Fee Related
- 2011-10-26 WO PCT/KR2011/008038 patent/WO2012057525A2/en not_active Ceased
- 2011-10-26 CN CN2011800563788A patent/CN103228265A/zh active Pending
- 2011-10-26 MX MX2013004595A patent/MX349441B/es active IP Right Grant
- 2011-10-26 BR BR112013010311A patent/BR112013010311A8/pt not_active Application Discontinuation
- 2011-10-26 CN CN201810170343.0A patent/CN108283714A/zh active Pending
- 2011-10-26 TW TW100138828A patent/TWI494120B/zh not_active IP Right Cessation
- 2011-10-26 JP JP2013536512A patent/JP6047495B2/ja not_active Expired - Fee Related
- 2011-10-26 AU AU2011321165A patent/AU2011321165B2/en not_active Ceased
- 2011-10-26 AR ARP110103966A patent/AR083568A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011321165A1 (en) | 2013-05-09 |
| TW201223541A (en) | 2012-06-16 |
| BR112013010311A2 (pt) | 2016-09-20 |
| RU2013124059A (ru) | 2014-12-10 |
| EP2632433A4 (en) | 2014-04-16 |
| MX2013004595A (es) | 2013-12-02 |
| US20130287734A1 (en) | 2013-10-31 |
| AU2011321165B2 (en) | 2015-11-05 |
| JP6047495B2 (ja) | 2016-12-21 |
| RU2613905C2 (ru) | 2017-03-21 |
| CA2816052A1 (en) | 2012-05-03 |
| CN108283714A (zh) | 2018-07-17 |
| US9669105B2 (en) | 2017-06-06 |
| JP2013544803A (ja) | 2013-12-19 |
| CA2816052C (en) | 2018-07-24 |
| CN103228265A (zh) | 2013-07-31 |
| WO2012057525A2 (en) | 2012-05-03 |
| TWI494120B (zh) | 2015-08-01 |
| MX349441B (es) | 2017-07-27 |
| EP2632433A2 (en) | 2013-09-04 |
| WO2012057525A3 (en) | 2012-06-28 |
| KR101303388B1 (ko) | 2013-09-03 |
| BR112013010311A8 (pt) | 2018-01-16 |
| KR20120043206A (ko) | 2012-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083568A1 (es) | FORMULACIONES LIQUIDAS DE CONJUGADO DE a INTERFERON DE ACCION PROLONGADA | |
| AR065639A1 (es) | Un complejo insulinotropico que utiliza un fragmento inmunogloblina | |
| ATE540327T1 (de) | Kontaktlinsenverpackungslösungen | |
| AR080427A1 (es) | Formulacion liquida para un conjugado de accion prolongada del g-csf | |
| CY1121356T1 (el) | Υγρο σκευασμα συζυγους ινσουλινης μακρας δρασης | |
| AR080993A1 (es) | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina | |
| AR124648A2 (es) | Suspensiones farmacéuticas submicrométricas estabilizadas y métodos para formar las mismas | |
| JP2012031421A5 (es) | ||
| WO2014017845A3 (en) | A liquid formulation of long acting insulinotropic peptide conjugate | |
| AR053806A1 (es) | Soluciones de solventes/polimeros como vehiculos de suspension | |
| AR068123A1 (es) | Productos de lentes de contacto | |
| AR079946A1 (es) | Formulaciones liquidas para conjugados de accion prolongada de eritropoyetina | |
| EA201590758A1 (ru) | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина | |
| CY1119038T1 (el) | Φαρμακευτικο εναιωρημα | |
| MX2012001204A (es) | Composiciones de polimero de acido hialuronico modificado y metodos relacionados. | |
| AR074959A1 (es) | Composicion acondicionadora de telas | |
| JP2011518842A5 (es) | ||
| JP2013525493A5 (es) | ||
| MX2015012213A (es) | Composicion de polietileno para el uso como bisagra viviente. | |
| AR094011A1 (es) | Composiciones para el cuidado oral | |
| RU2014101988A (ru) | Медицинские материалы | |
| AR082032A1 (es) | Complejo de factor viia en el que se utiliza un fragmento de inmunoglobulina | |
| PE20131337A1 (es) | Composicion anestesica nanoparticulada para la administracion topica | |
| JP2017523783A5 (es) | ||
| EP4001323A4 (en) | ACRYLIC RUBBER LAYER WITH GOOD PRESERVATION STABILITY AND PROCESSABILITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |